Esplora il catalogo della ricerca


Ricerca avanzata
Scopri
Tipologia
  • 03. Contributo in rivista70419
  • 02. Contributo in libro27364
  • 04. Contributo a convegno7142
  • 01. Libro4776
  • 05. Curatela3148
  • 06. Altra tipologia1925
  • 07. Brevetto25
Data di pubblicazione
  • 2020 - 202425692
  • 2010 - 201959854
  • 2000 - 200922333
  • 1990 - 19995121
  • 1980 - 19891542
  • 1970 - 1979237
  • 1960 - 196919
  • 1955 - 19597

Prodotti recenti
RSS Feed RSS Feed RSS Feed

Le nuove dinamiche della fase preliminare

Il contributo analizza la fase delle indagini alla luce delle più recenti modifiche normative

Disentangling Support for Violent and Non-violent Radicalization among Adolescents: A Latent Profile Analysis

Although support for violent and non-violent radicalization can co-occur, only a few adolescents who support non-violent radicalization also support or engage in violent acts. Yet, little is known about what factors are associated with adolescents’ paths towards or away from violent and/or non-violent radicalization. Within a socio-ecological and positive youth development framework, this study investigates profiles of support for violent and non-violent radicalization among adolescents attend...

Les objets en tant que médiateurs de la communication chez les enfants atteints de troubles du spectre autistique

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomid...

RWD129 Cost Effectiveness of Onasemnogene Abeparvovec in Infants with Presymptomatic Spinal Muscular Atrophy in Italy

Objectives Spinal muscular atrophy (SMA) is a devastating rare disease and the most common genetic cause of infant death. Patients with SMA are lacking survival motor neuron 1 (SMN1) gene, leading to reduced SMN protein, loss of functional motor neurons, and progressive, debilitating and often fatal muscle weakness. Though SMN1-targeting treatments like onasemnogene abeparvovec, a one-time gene therapy infusion, can be costly, they provide significant motor improvements in patients with SMA....